INAMED CORP
NT 10-Q, 1997-05-16
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Previous: CERIDIAN CORP, 8-K, 1997-05-16
Next: GRC INTERNATIONAL INC, 424B3, 1997-05-16





                          United States
               SECURITIES AND EXCHANGE COMMISSION
                                
                     Washington, D.C.  20549
                                
                                


                           FORM 12b-25
                                
                   NOTIFICATION OF LATE FILING
                                
                          (Check one):
                                
[ ]Form 10-K   [ ]Form 20-F  [ ]Form 11-K   [X]Form 10-Q  [ ]Form N-SAR

For Period Ended: March  31, 1997

[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR

For the Transition Period Ended:

Read Attached Instruction Sheet Before Preparing Form.  Please
Print or Type.

Nothing in this form shall be construed to imply that the
Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked
above, identify the Item(s) to which the notification relates:

Not applicable


Part I - Registrant Information

Full Name of Registrant

INAMED CORPORATION

Address of Principal Executive Office:

3800 Howard Hughes Parkway, Suite #900
Las Vegas, Nevada  89109

Part II - Rules 12b-25 (b) and (c)

If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to
Rule 12b-25(b), the following should be completed.  (Check box if
appropriate)

[X]       (a) The reasons described in reasonable detail in Part
III of this form could not be eliminated without unreasonable effort
or expense;

[ ]       (b) The subject annual report, semi-annual report,
transition report on Form 10-K, Form    20-F, 11-K or From N-SAR,
or portion thereof will be filed on or before the fifteenth calendar
day following the prescribed due date; or the subject quarterly report
or transition report on Form 10-Q, or portion thereof will be filed
on or before the fifth calendar day following the prescribed due date; and

[ ]       (c) The accountant's statement or other exhibit required by
Rule 12b-25(c) has been attached if applicable


Part III - Narrative

State below in reasonable detail the reason why Form 10-K, 20-F,
11-K, 10-Q, N-SAR or the transition report or portion thereof
could not be filed within the prescribed time period.

As previously disclosed in press releases dated April 1, April
15, May 8 and May 15, 1997, the Company was unable to timely file
its annual report on Form 10-K for calendar/fiscal year 1996.
Because the Form 10-K has not yet been completed, the Form 10-Q
for the first quarter 1997 could not be filed within its
prescribed time period without unreasonable effort or expense.
The Company expects to file Form 10-Q concurrently with the Form
10-K, which it anticipates filing before June 5, 1997.

Part IV - Other Information

(1) Name and telephone number of person to contact in regard to
this notification

Samuel L. Simmons, Jr. , VP Finance, Treasurer
INAMED Corporation  (702) 791-3388

(2) Have all other periodic reports required under section 13 or
15 (d) of the Securities Exchange Act of 1934 or section 30 of
the Investment Company Act of 1940 during the preceding 12 months
or for such shorter periods that the registrant was required to
file such report(s) been filed? If the answer is no, identify
report(s).
                              [ ] Yes   [X] NO

Form 10-K for the period ended December 31, 1996

(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year
will be reflected by the earning statements to be included in the
subject report or portion thereof?

                              [ ] Yes   [X] NO

If so: attach an explanation of the anticipated change, both
narratively and quantitatively, and if appropriate, state the
reasons why a reasonable estimate of the results cannot be made.
                                
                                
                       INAMED CORPORATION

has caused this notification to be signed on its behalf by the
undersigned thereunto duly authorized.

Date:  May  16,  1997               By /s/  Donald  K. McGhan
                                    Chairman of the Board and CEO



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission